Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26124498 | 0.80 | — | — | |
| SCHEMBL31691787 | 0.80 | — | — | |
| SCHEMBL4791253 | 0.79 | MAPT (0.46) | GRM5MAPK1 | |
| SCHEMBL4867797 | 0.76 | LMNA (0.32) | P2RX7GRM5 | |
| SCHEMBL4865954 | 0.76 | DPP4 (0.35) | P2RX7GRM5MAPK1 | |
| SCHEMBL19547099 | 0.74 | P2RX7 (0.42) | P2RX7HSP90AA1HSP90AB1HSP90B1MTHFD2 | |
| SCHEMBL4867800 | 0.72 | HDAC1 (0.42) | P2RX7HSP90AB1GRM5NPC1RAB9A | |
| SCHEMBL4266981 | 0.70 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL2550300 | 0.69 | HRH4 (0.35) | P2RX7 | |
| SCHEMBL1014080 | 0.68 | GRM5 (0.38) | P2RX7HSP90AA1HSP90AB1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | P2RX7 1401/4885HSP90AA1 3454/4885HSP90AB1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.